Phase 3 N=3,388 Safety Study of ProQuad® rHA in Infants (V221-037)
Measles · Mumps · Rubella
Primary: Percentage of Participants Experiencing an Adverse Event (AE) After ProQuad® Dose 2 — 57.66 Percentage of Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=388 Dysport® Adult Lower Limb Spasticity Study
Leg Spasticity
Primary: Least Squares Mean Change From Baseline to Week 4 in the MAS Score in the Gastrocnemius-soleus Complex (GSC) (Knee Extended) — -0.6; -0.8; -0.5 units on a scale…
Phase 3 N=708 Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Dermatitis, Atopic
Primary: Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 16 — 8.5; 36.1; 36.4…
Phase 3 N=104 A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection
Chronic Hepatitis C Virus (HCV) Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 98.1 percentage of participants
Phase 3 N=3,006 Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)
HPV Infections
Primary: Base Study: Combined Incidence of 6-Month Persistent Infection, Cervical Intraepithelial Neoplasia (CIN+), and External Genital Lesions Related to Human Papillomavirus…
Phase 3 N=438 OTX-15:003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery
Post-Surgical Ocular Pain · Post-Surgical Ocular Inflammation
Primary: Absence of Anterior Chamber Inflammation — 52.3; 31.1 percentage of total participants
Phase 3 N=48 Hip Fracture Study of GSK576428 (Fondaparinux Sodium)
Thromboembolism
Primary: Rate of Major Bleeding During Treatment Period — 21.6 % of normalized events per participant
Phase 3 N=1,231 A Safety and Immune Study of 2 Types of GlaxoSmithKline's Varicella Vaccines Given as a 2-doses Course to Healthy Children 12-23 Months of Age.
Chicken-pox Illness (Varicella Virus Disease) · Chickenpox
Primary: Number of Subjects Reporting Fever — 24; 32 Subjects
Phase 3 N=100 A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
Allergic Conjunctivitis
Primary: Ocular Itching at Duration of Action (8 Hours + 30 Minutes Post-dose) — 1.76; 2.69; 1.85; 2.74 units on a scale
Phase 3 N=2,840 Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Breast Cancer
Primary: Invasive Disease-free Survival (iDFS) in Neratinib Arm Compared to Placebo Arm at Year 2 — 4.7; 7.5 percentage of participants with events — p=0.008
Phase 3 N=2,174 A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)
Urinary Bladder Diseases · Urinary Bladder Overactive · Urologic Diseases
Primary: Change From Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes Per 24 Hours — -1.8; -1.53; -1.67 incontinence episodes — p==0.001
Phase 3 N=588 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
Adult Alveolar Soft-part Sarcoma · Adult Angiosarcoma · Adult Epithelioid Sarcoma
Primary: Probability for Event Free Survival. — 0.8984; 0.7647; 0.6079; 0.4873 Probability of EFS at 5 years
Phase 3 N=160 Safety and Efficacy of the Propel Mini and Propel Nova Steroid-Eluting Sinus Implant in Frontal Sinus
Chronic Sinusitis
Primary: Percent of Sinuses That Require Post-operative Interventions (Propel Mini Cohort) — 38.8; 62.7 percent sinuses requiring intervention
Phase 3 N=1,501 Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects
Infections, Meningococcal · Meningococcal Vaccines
Primary: Number of Subjects With Vaccine Response to N. Meningitidis Serogroups A (MenA), MenC, MenY and MenW-135 — 529; 124; 664; 210 Participants
Phase 3 N=145 A Multicenter Extension Trial to Evaluate the Safety of Testosterone Gel
Adult Male Hypogonadism
Primary: Percentage of Subjects With a Serum Total Testosterone Level - Maximum Observed Concentration (Cmax) of 1500-1799, 1800-2499, or Above 2500 ng/dL — 5.7; 2.8; 2.8…